Methylprednisolone/prednisolone Reactions 1680, p227 - 2 Dec 2017 Hallucinations and delusions: case report In a retrospective study of 15 patients, a teenage girl was described [age at the time of reaction onset not clearly stated], who developed hallucinations and delusions following treatment with prednisolone and methylprednisolone [routes, time to reactions onset and outcomes not stated]. In 2004, at the age of 15 years, the girl was diagnosed with an familial myasthenia gravis. Later, she was started on oral prednisolone with an initial dose of 10 mg/day. Subsequently, the dose of prednisolone was slowly increased to 40 mg/day as the maximum maintenance dose. However, symptoms of myasthenia gravis persisted. In February 2005, she experienced respiratory difficulties consistent with dysphagia and paralysis of the respiratory muscles, which required ventilation. Later, she was started on a high dose methylprednisolone 1 g/day for 5 days. She also received gammaglobulin. Eventually, symptoms of myasthenia gravis improved. However, she developed significant psychiatric symptoms including hallucinations and delusions, which were considered as side effects of the corticosteroid therapy. Therefore, the girl’s methylprednisolone dose was gradually reduced and later stopped. She was treated with psychotolytic drugs. Author comment: "All patients responded well to immunosuppressants and psychiatric symptoms were observed in one patient who received a high dose of corticosteroids." "Meanwhile, significant psychiatric symptoms were noted, including hallucinations and delusions. Due to its side effects, steroid was gradually decreased and stopped." Feng H-Y, et al. A retrospective review of 15 patients with familial myasthenia gravis over a period of 25 years. Neurological Sciences 33: 771-777, No. 4, Aug 2012. Available from: URL: - China 803285026 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial